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The role of angiotensin-(1-7) in 
renal vasculature of the rat 
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Angiotensin-(1-7) [Ang(1-7)] is an active component of the renin-angiotensin-aldosterone system. Its 
exact role in renal vascular function is unclear. We therefore studied the effects of Ang(1-7) on the renal 
vasculature in vitro and in vivo. 
 
Methods 
Isolated small renal arteries were studied in an arteriograph system by constructing concentration-
response curves to angiotensin II (Ang II), without and with Ang(1-7). In isolated perfused kidneys (IPK), 
the response of Ang II on renal vascular resistance was measured without and with Ang(1-7). The 
influence of Ang(1-7) on Ang II-induced glomerular afferent and efferent constriction was assessed with 
intravital microscopy in vivo under anaesthesia. In freely moving rats, we studied the effect of Ang(1-7) 
on Ang II-induced reduction of renal blood flow (RBF) with an electromagnetic flow probe. 
 
Results 
Ang(1-7) alone had no effect on the renal vasculature in any of the experiments. In vitro, Ang(1-7) 
antagonised Ang II-induced constriction of isolated renal arteries (9.71±1.21% and 3.20±0.57%, for 
control and Ang(1-7) pretreated arteries, respectively; p<0.0005). In IPK, Ang(1-7) reduced the Ang II 
response (100±16.6 versus 72.6±15.6%, p<0.05) and shifted the Ang II dose-response curve rightward 
(pEC50 6.69±0.19 and 6.26±0.12 for control and Ang(1-7) pretreated kidneys, respectively; p<0.05). 
Ang(1-7), however, was devoid of effects on Ang II-induced constriction of glomerular afferent and 
efferent arterioles and on Ang II-induced RBF reduction in freely moving rats in vivo. 
 
Conclusion 
Ang(1-7) antagonises Ang II in renal vessels in vitro, but does not appear to have a major function in 
normal physiological regulation of renal vascular function in vivo. 
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Angiotensin II (Ang II) is the main effector peptide of the renin-angiotensin-aldosterone system. In the 
renal vasculature, it is a potent vasoconstrictor and it regulates kidney function by modulating the 
glomerular filtration rate, renal blood flow (RBF), and renal vascular resistance (RVR). There is 
increasing evidence, however, that apart from Ang II, other components of the renin-angiotensin-
aldosterone system are biologically active. In particular, angiotensin-(1-7) [Ang(1-7)], which consists of 
the first seven amino acids of angiotensin I (Ang I) and Ang II, is thought to play a role in counteracting 
the response to Ang II1. It is produced through cleavage of Ang I and Ang II by neutral endopeptidases, 
and from the recently discovered angiotensin-converting enzyme (ACE) homologue ACE22. 
The pharmacological mechanisms and the receptors involved in the effects of Ang(1-7) are 
diverse. First, because Ang(1-7) is a substrate for ACE, it acts as an ACE inhibitor3. Second, Ang(1-7) is 
an antagonist of the angiotensine type 1 receptor (AT1R)4;5, but in higher doses AT1R agonistic effects 
are also observed6. Third, there is some evidence for angiotensin type 2 receptor (AT2R) agonism for 
Ang(1-7)7, although the main receptor for Ang(1-7) appears to be the newly discovered Ang(1-7) 
receptor, Mas8. Through Mas receptor stimulation, Ang(1-7) potentiates bradykinin-induced effects9, 
stimulates release of prostanoids10 and releases nitric oxide (NO)11. 
Ang(1-7) may play an important role; not only in normal physiology, but it may also contribute to 
the therapeutic effects of ACE inhibition, as plasma levels of Ang(1-7) are increased during therapy with 
ACE inhibitors12;13. Moreover, Ang(1-7) has been shown to attenuate the development of heart failure14 
and to inhibit neointimal formation after stent implantation15, features which are similar to those of ACE 
inhibitors. As ACE inhibitors are widely applied in various forms of renal disease and hypertension, 
Ang(1-7) may be applied as a new pharmacological agent in renovascular diseases. 
The role of Ang(1-7) in the (patho)physiological regulation of kidney function is still not completely 
understood, however, and the current literature shows conflicting data. Diuresis and natriuresis have 
been documented10;16-19, in which the release of prostanoids10, inhibition of tubular Na+ reabsorption 
after stimulation of both AT1R and non-AT1R/non-AT2R18, and Mas receptor stimulation19 appear to play 
a role. In addition, Ang(1-7) is a vasodilator in rabbit afferent arterioles through the release of NO after 
Mas receptor stimulation20. It also inhibits Ang II-induced vasoconstriction in isolated perfused kidneys 
(IPK)5. Blood pressure is lowered in response to Ang(1-7)17, an effect mediated by Mas receptors21, 
through the release of prostanoids22 and NO23 and the potentiation of bradykinin24 and acetylcholine-
induced NO release25. 
In other studies, however, Ang(1-7) was without effect or had even opposing effects on the kidney. 
In water-loaded rats, Ang(1-7) exerted an antidiuretic and antinatriuretic effect through Mas receptors26; 
and in hydronephrotic IPK, Ang(1-7) acted as a vasoconstrictor by stimulation of AT1R6. In addition, 
hypertensive effects of Ang(1-7) through AT1R stimulation have been described27. Differences in 
experimental models and protocols, such as in vitro versus in vivo studies, the use of anaesthetics, 






for these discrepancies. Because the effects of Ang(1-7) on renal vascular physiology are poorly 
characterised, we aim to establish the role of Ang(1-7) at several levels of the renal vasculature. 
We therefore studied the effect of Ang(1-7) and its effect on the response to Ang II in isolated renal 





Male Wistar rats (320-350 g; n=40) were housed under standard conditions with free access to food and 
drinking water. Rats received a standard chow diet containing 0.3% NaCl (Hope Farms Inc., Woerden, 
The Netherlands). Animal experiments were approved by the institutional animal ethical committee. 
Isolated small renal interlobar arteries 
Kidneys (n=6) were removed under isoflurane/O2/N2O anaesthesia. Small renal interlobar arteries with 
an internal diameter of 250-300 μm were dissected and transferred to a pressurised arteriograph 
system. Artery segments were cannulated on glass micropipettes at both ends, secured, and perfused 
with Krebs solution (120.4 mM NaCl, 5.9 mM KCl, 2.5 mM CaCl2, 1.2 mM MgCl2, 1.2 NaH2PO4, 25.0 
mM NaHCO3, 1.2 mM glucose, oxygenated with 5% CO2 in O2, pH 7.4, and 37 °C). Intraluminal pressure 
was set to 70 mmHg and held constant (blind sac) by a pressure servo system. The vessel chamber 
was transferred to the stage of an inverted light microscope with a video camera attached to a viewing 
tube. A video dimension analyser was used to register lumen diameter continuously. 
Arteries were allowed to equilibrate for 1 h in Krebs solution. Experiments were performed in the 
presence of the nitric oxide synthase inhibitor, NG-monomethyl-L-arginine (10-4 M, 20 min), and the ACE 
inhibitor, lisinopril (10-6 M, 15 min), to block NO-dependent relaxation and to prevent degradation of 
Ang(1-7) by ACE, respectively. Subsequently, dose-response curves to cumulative doses of Ang II    
(10-10 to 10-6 M), with and without Ang(1-7) (10-5 M, 10 min), were constructed by adding Ang II directly 
to the bath. Constriction responses are expressed as percentage of baseline lumen diameter. 
 
Isolated perfused kidneys 
Carbogenated Krebs-Ringer bicarbonate (KRB) buffer, pH 7.4 (118 mM NaCl, 4.69 mM KCl, 1.18 mM 
KH2PO4, 1.18 mM MgSO4·7H20, 25 mM NaHCO3, 2.52 mM CaCl2·2H2O), supplemented with D-glucose 
(1.1 g/L) was used. The IPK setup consisted of a moist temperature chamber in which the kidney was 
perfused through a cannula in the renal artery using a peristaltic pump. KRB was oxygenated with a 
mixture of 95% O2/5% CO2 by a capillary module, and passed through a bubble trap. Temperature was 
kept at 37 °C with a thermostatically controlled water bath. 
Rats were anaesthetised with isoflurane/O2/N2O, the abdomen was opened by a mid-line incision, 
and the aorta (rostral from the right renal artery) and the superior mesenteric artery were ligated. Blood 
was removed from the kidneys by flushing them through the aorta with 10 ml of KRB at 37 °C. The 
56 
The role of Ang(1-7) in renal vasculature 
 
 
kidneys and aorta were removed en bloc and placed on ice. The renal arteries were cannulated, and 
remaining blood was removed by flushing the kidneys with KRB at 4 °C. Subsequently, the kidneys 
were transferred to the IPK setup and perfused with KRB at a continuous flow of 10 ml/min. Perfusion 
pressure was continuously monitored. After 15 minutes of equilibration, dose-response curves to Ang II 
were constructed by injection of 100 µl of Ang II solutions (10-9 to 10-4 M) in the buffer in close proximity 
to the kidney. Subsequently, Ang(1-7) was added to the buffer reservoir in a final concentration of 10-5 
M, and after 15 minutes of equilibration, the dose-response curve of Ang II was repeated. Renal 
vascular resistance is expressed as percentage of maximal pressure rise (ΔP) in response to Ang II. 
 
Intravital microscopic analysis of afferent and efferent arterioles 
The experimental system consisted of a pencil-probe video microscope with a corn-shaped lens (optical 
magnification 3.5x) and a charge-coupled device (CCD) camera (Nihon Kohden, Tokyo, Japan), a 
micromanipulator, a xenon light source (LB-18 Welch Allyn, Tokyo, Japan), a monitor (KLV-17HR1, 
Sony, The Netherlands), a DVD recorder (RDR-GX7), and a computer for image analysis (Intel P4). The 
lens fitted with a 12.7 mm greyscale CCD image sensor (XC ES55L, Toshiba, Tokyo, Japan) at the 
focal length (200 mm) of the lens. A green filter to complement red was placed in front of a CCD image 
sensor to enhance the contrast on the monitor between vessels and peripheral tissue. The CCD image 
sensor was connected to camera module (DC700, Tokyo, Japan) and images were recorded as stacked 
image film (30 frames/s). The final spatial resolution of the video microscope was confirmed to be 0.86 
µm with electrical magnification of 520x. The scale of the captured video image was 752x582 pixels on 
the display, which allowed us to monitor only one glomerulus and its region in each experimental 
protocol. 
For the experiments, rats were briefly anaesthetised with isoflurane/O2/N2O to insert a cannula in 
the tail vein. Through this cannula, 100 µg/kg of thiobutabarbital (Inactin®, Sigma-Aldrich, Zwijndrecht, 
The Netherlands) was injected in two doses, and if necessary re-administered to maintain a constant 
level of anaesthesia. In addition, the operation regions were locally anaesthetised with lidocaine (20 
mg/ml). The carotid artery and jugular vein were cannulated for measurement of arterial blood pressure 
and heart rate, and intravenous infusion of angiotensins, respectively. Subsequently, the abdomen was 
opened by mid-line incision and the left renal artery was exposed. For measuring renal blood flow, an 
ultrasonic flow probe (model 1RB, Transonic Systems, Ithaca, New York, USA) was placed around the 
left renal artery and the RBF was continuously registered with a flow meter (model T106, Transonic 
Systems). The blood pressure and heart rate were recorded using a pressure transducer (Edwards 
Lifesciences S.A., Saint-Prex, Switzerland) and amplifier (model AP641G, Nihon Kohden). The capsule 
of the renal cortex was removed, and a small slice of the renal surface was removed (maximum depth 
0.5 mm) using a scalpel. The tip of the pencil-probe CCD video microscope was then guided to the 
bottom of the excision. Superficial glomeruli in which afferent and efferent arterioles could be confirmed 
and blood flow was not influenced by surgical insult were used in the experiment. One glomerulus per 





The image at each measurement point was captured as a stack of 60 frames (2 s) using an image 
capture board (LG-3, Scion Computer Service, Frederick, Maryland, USA) installed in the image 
analysis computer. Clear frames not influenced by respiration and heartbeat were selected from the 60 
frames in the captured stacks and analysed. To measure afferent and efferent diameters, image 
software (Scion Corporation, Frederick, Maryland, USA) was used. Diameters were measured after 
calibration of the number of pixels with a microscope calibration glass. 
Dose-response curves to Ang II were constructed by intravenous infusion of doses of 3, 10, and 30 
ng/kg/min (10 min each). In other rats, responses to increasing doses of Ang II were measured, after 
stabilisation (10 min) on intravenous Ang(1-7) administration (300 ng/kg/min). Beside afferent and 
efferent arteriole diameter, mean arterial blood pressure (MAP), heart rate (HR), and RBF values were 
recorded at each measurement point. 
 
Renal blood flow in freely moving rats 
Rats were anaesthetised with pentobarbital (60 mg/kg), and the abdomen was opened by mid-line 
incision. The left renal artery was dissected and an electromagnetic flow probe (type P0.7, Skalar 
Medical, Delft, The Netherlands) was placed around the left renal artery. A catheter was placed in the 
jugular vein to allow intravenous infusion of angiotensins (in 5% glucose, 3 ml/h). Both the wire of the 
probe and the catheter were tunnelled subcutaneously and attached to the skull of the animal using 
stainless steel screws and dental cement. After recovery, the flow probe was connected to a sensor 
adapter (MDL 450, Skalar Medical), which was coupled to a velocity meter (MDL 401, Skalar Medical). 
The effect of Ang II (1, 2, 5, 10, 15, and 30 ng/kg/min) on RBF was studied. After Ang II, Ang(1-7) was 
administered (333 or 667 ng/kg/min). Subsequently, the RBF response to Ang II was measured in the 
presence of Ang(1-7). 
In a second series of experiments, Ang II was infused in one dose (10 ng/kg/min). This was 
repeated after stabilisation on intravenous infusion of Ang(1-7) in doses of 133, 333, and 667 ng/kg/min 
in the same animal on the same day, which allowed each animal to serve as its own control. 
 
Statistical analysis 
Data are expressed as mean ± SEM. Dose-response curves are compared for statistical differences by 
general linear model analysis of variance. For other comparisons a paired-samples t-test was 
performed. Differences were considered significant at p-value less than 0.05. 
 
Results 
Isolated small renal arteries 
Ang(1-7) alone had no effect on the diameter of isolated small renal arteries (data not shown). In the 
presence of NG-monomethyl-L-arginine and lisinopril, Ang II dose-dependently contracted these arteries, 
reaching its maximum effect at 10-6 M with a maximum effect (Emax) amounting to 9.71±1.21% of the 
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initial baseline diameter. This response was completely blocked by additional incubation of the vessels 
with Ang(1-7) (10-5 M) in the whole concentration range (Emax = 3.20±0.57%, p<0.0005) (Fig. 1). 
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Figure 1. Ang(1 7) inhibits the vasoconstrictor response to Ang II in isolated small interlobar renal a teries. Ang II-
induced constriction of small renal interlobar arteries (n=6) in the presence of L-NMMA and lisinopril. Ang(1-7) (10
-     r
-5 M) 
completely blunted the constrictive response to Ang II (***p<0.0005). 
 
Isolated perfused kidneys 
Ang(1-7) alone did not affect renal vascular resistance (RVR) in isolated perfused kidneys (data not 
shown). Ang II dose-dependently increases RVR, with maximum values after injection of 10-5 M and 
reaching a half-maximal response at a negative log-concentration (pEC50) of 6.69±0.19 (Fig. 2). In the 
presence of Ang(1-7) (10-5 M), the maximal response to Ang II was reduced (100±16.6 and 72.6±15.6% 
for control and Ang(1-7), respectively; p<0.05) and the dose-response curve of Ang II was significantly 
shifted rightward (pEC50 6.26±0.12, p<0.05) (Fig. 2). 
 
Intravital microscopic analysis of afferent and efferent arterioles 
To extend these in vitro findings, we performed similar experiments in the whole rat, evaluating 
glomerular arteriolar diameter using intravital microscopy under anaesthesia. Ang(1-7) alone had no 
effect on afferent and efferent arteriolar diameter, and on the MAP and RBF (data not shown). 
Glomerular afferent and efferent arterioles showed a dose-dependent constriction in response to 
systemic Ang II infusion (3-30 ng/kg/min; Fig. 3A, B). The response to Ang II in the afferent arteriole was 
unaffected by Ang(1-7) infusion (Fig. 3A). In efferent arterioles, Ang(1-7) (300 ng/kg/min) diminished 





infusion with Ang II alone did not significantly affect the MAP, a significant increase in MAP by Ang II 
was observed in the presence of Ang(1-7) (p<0.005). Ang II dose-response curves of the Ang II effect 
on MAP in the absence and presence of Ang(1-7) were still not significantly different (p=0.509) (Fig. 
3C). In addition, Ang II strongly reduced RBF. Ang(1-7) did not attenuate the Ang II-mediated reduction 
in RBF (Fig. 3D). 
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Figure 2. Ang(1-7) inhibits the Ang II-induced increase in renal vascular resistance in isolated perfused kidneys. Dose-
dependent increase in renal vascular resistance by Ang II in isolated perfused kidney setup (n=4). Pre-incubation of 
the kidneys with Ang(1-7) (10
 
-5 M) results in a rightward shift of the Ang II dose-response curve and depression of the 
maximum response to Ang II. *p<0.05 
 
Renal blood flow in freely moving rats 
Ang(1-7) alone had no effect on the baseline RBF (data not shown). Ang II reduced renal blood flow in 
freely moving rats. Ang(1-7) did not inhibit the RBF response to Ang II in doses of 333 and 667 
ng/kg/min (Fig. 4A). Because of the large interindividual variability in response to Ang II, a second flow 
experiment was designed in which each animal served as its own control. Figure 4B shows that the 
renal blood flow is equally reduced by Ang II either in the absence or presence of Ang(1-7) (133, 333 
and 667 ng/kg/min). 
 
Discussion 
The present study shows that Ang(1-7) alone has no effect on baseline renal vasomotor tone in any of 
the in vitro and in vivo experimental setups used. Second, Ang(1-7) attenuates the response to Ang II in 
isolated small renal arteries and IPK in vitro. No significant effects of Ang(1-7), however, were found on 
afferent and efferent arteriolar responses to Ang II in anaesthetised rats. Moreover, in freely moving rats 
the RBF reduction in response tot Ang II did also not change upon infusion of Ang(1-7). 
60 






























































































Figure 3. Ang(1-7) does not attenuate the vasoconstrictive esponse to Ang II in afferent and efferen  
arterioles, and enal blood flow in vivo under anaesthesia. Intravital microscopy experiment with dose-
response curves for Ang II with (●) and without (○) Ang(1-7) infusion (300 ng/kg/min). Ang II dose-
response curves are shown for afferent arterioles (A), efferent arterioles (B), mean arterial pressure 
(MAP) (C), and renal blood flow (RBF) (D). Ang II did not affect MAP, but dose-dependently reduced 
afferent and efferent arteriole diameter, and RBF. Ang(1-7) did not significantly affect the response of 
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Figure 4. Ang(1-7) does not modulate the effect of Ang I on renal blood flow in freely moving ats. 
Intravenous infusion of Ang II reduced renal blood flow (RBF) (n=14). Ang(1-7) doses of 333 (n=4) and 
667 ng/kg/min (n=6) could not inhibit the RBF reduction by Ang II (A). In additional experiments (n=5), 
Ang(1-7) in doses of 133, 333, and 667 ng/kg/min, did not antagonise the RBF response to Ang II in the 
same rat (B). 
I  r
 
The finding that Ang(1-7) blocks in vitro constriction of renal vessels by Ang II, but has no 
important role in the regulation of in vivo RBF in normotensive rats is in agreement with other studies. 
Indeed, evidence for an antagonistic effect of Ang(1-7) on Ang II-induced renal vasoconstriction is 
achieved in vitro5;20, whereas the effect of Ang II on RBF could not be blocked by Ang(1-7) in vivo18. 
Intriguingly, the finding on the effect of Ang(1-7) thus differs between different experimental 
designs. Several factors may contribute to the discrepancy between these different experimental 
protocols. First, the pharmacokinetics of Ang(1-7) may be important. Due to rapid degradation by ACE, 
Ang(1-7) has a plasma half-life of only 10 seconds in rats31. Despite this unfavourable pharmacokinetic 
property, we previously found increased plasma Ang(1-7) levels after infusion of similar doses of  
Ang(1-7)14;32. Such Ang(1-7) plasma levels, however, were considerably lower (nM range) than the 
concentrations used in the in vitro experiments (µM range). One could speculate that not plasma levels 
but renal tissue levels of Ang(1-7) are important for its response. Because we found no effects of  
Ang(1-7) in vivo, this would implicate that, in this study, renal levels of Ang(1-7) were insufficiently 
increased by intravenous infusion. Consequently, our data implicate that intravenous administration 
raises local concentration of Ang(1-7) insufficiently to inhibit renal ACE or antagonise AT1R, which 
matches previous observations demonstrating that the effects of systemic Ang(1-7) on kidney are 
mediated by the Mas receptor19;26. 
A second reason for our discrepant results may be that responses were measured at different 
anatomical levels of the renal vasculature, each with its specific role in the regulation of renal vascular 
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tone. Small renal interlobar arteries are preglomerular vessels that may be contributing to the total RVR 
only to a limited extent. In IPK both preglomerular and postglomerular vasoconstriction determine the 
overall RVR; but the majority of the RVR is determined by preglomerular vasoconstriction, in particular 
by constriction of afferent arterioles, which contribute to 50% of preglomerular resistance33. Therefore, 
although both interlobar arteries and IPK assess (mainly) preglomerular vessels, RVR is probably more 
closely represented in IPK. In contrast, RBF is mainly determined by efferent vasoconstriction, although 
afferent arteriolar diameter also contributes to a limited extent. An Ang II-antagonising effect of Ang(1-7) 
in interlobar arteries and IPK is therefore not necessarily in conflict with the absence of such an effect of 
Ang(1-7) on RBF. Our intravital microscopy data do not, however, match the IPK experiments as an 
Ang II-antagonising effect of Ang(1-7) on afferent vessels was not confirmed. This could be explained if 
the Ang II-antagonising effect of Ang(1-7) in IPK results from effects on larger preglomerular vessels. 
The different effects of Ang(1-7) in the different renal vascular beds may be the result of different 
levels of angiotensin receptors in the larger preglomerular arteries, afferent arterioles, and efferent 
arterioles. Our data may indicate that in larger preglomerular vessels either Mas receptors or AT2 
receptors are present, while they are absent in afferent and efferent arterioles. In IPK, however, the Ang 
II-antagonising effect of Ang(1-7) was previously shown to be mediated by an antagonistic effect on 
AT1R5. Furthermore, there are currently no data about the exact localisation of Mas receptors within the 
kidney, but their presence is likely in rabbit afferent arterioles20. For AT2R, it is known that they are 
present in larger vessels34 and in both afferent35 and efferent arterioles36 of the rat. Therefore it is 
unlikely that the different Ang(1-7) effects are resulting from different receptor distributions in the renal 
vascular beds. It consequently seems more obvious that the effects of Ang(1-7) as observed in vitro are 
counterbalanced in vivo. 
Another confounding factor in establishing the effects of Ang(1-7) may be the application of 
anaesthesia. Anaesthesia is known to have major influences on haemodynamics, including reduction of 
blood pressure and peripheral resistance. Although thiobutabarbital is an anaesthetic with minimal 
effects on haemodynamics37, the glomerular filtration rate and RBF are reduced during thiobutabarbital 
anaesthesia, implying that renal vasomotor tone is affected by this anaesthetic38. In this study, therefore, 
the effects of Ang(1-7) were measured both under anaesthesia and in freely moving rats; however, we 
found no effect of Ang(1-7) on Ang II-reduced RBF even without anaesthesia, indicating that efferent 
Ang II-antagonising effects of Ang(1-7) are absent in vivo and not blunted by narcosis. 
Several other factors may be contributing to the discrepant effects of Ang(1-7) in vitro and in vivo, 
including innervation, circulating neurohumoral substances and blood pressure regulation. Innervation 
may play an important role as the renal vasculature is highly innervated39, and it is known to be 
important in the regulation of renal vascular tonus, in particular for afferent and efferent arterioles40. 
Consequently, the renal vasculature is less preconstricted in IPK than when it is left in situ, which may 
have major influences on the effects of Ang II and Ang(1-7). Furthermore, circulating neurohumoral 
substances such as NO and prostaglandins may be increased in vivo by Ang II alone41, which may 





NO and prostaglandins. In addition, the increase in blood pressure by Ang II in vivo may increase renal 
vascular tone and consequently mask potential effects of Ang(1-7). 
Together, these data suggest that Ang(1-7) blocks Ang II mediated renal vasoconstriction in vitro 
on preglomerular vessels, but does not counterbalance Ang II in regulating renal afferent and efferent 
vasomotor tone in vivo. Detailed study on the distribution of Mas receptor in the renal vasculature is 
pivotal to expand our understanding of this phenomenon. 
In conclusion, Ang(1-7) is antagonist of Ang II in isolated small renal arteries and IPK. Ang(1-7) 
does not, however, appear to have a major function in the normal physiological regulation of renal 
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